This website is developed and sponsored by Consilient Health. This site has been developed as a source of medicine information for healthcare professionals or patients who have been prescribed Mysimba®
This website is not intended for the general public.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2 | Tel: +353 1 6764971 | Fax: +353 1 6762517 Website: www.hpra.ie | e-mail: firstname.lastname@example.org
Adverse events should also be reported to Nalpropion Pharmaceuticals LLC: (800) 793-2145 or APV.AECurrax@primevigilance.com
For all other queries, please contact Consilient Health at Tel: +353 (0)1 2057760 | Fax: +353 (0)1 2698919 or email@example.com
Product Authorisation Number: EU/1/14/988/001-002
IE-MYS-146a | Date of preparation: December 2020